Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance
出版年份 2021 全文链接
标题
Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance
作者
关键词
Clinical trials, Drug repurposing, Host directed therapeutics, Nanoparticles, TB drug discovery pipeline
出版物
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 229, Issue -, Pages 114066
出版商
Elsevier BV
发表日期
2021-12-26
DOI
10.1016/j.ejmech.2021.114066
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Easily accessed nitroquinolones exhibiting potent and selective anti-tubercular activity
- (2021) Phelelisiwe S. Dube et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Evaluating bedaquiline as a treatment option for multidrug-resistant tuberculosis
- (2021) Marta Martín-García et al. EXPERT OPINION ON PHARMACOTHERAPY
- Comparative efficacy of the novel diarylquinoline TBAJ-587 and bedaquiline against a resistant Rv0678 mutant in a mouse model of tuberculosis
- (2021) Jian Xu et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Host‐directed therapy to combat mycobacterial infections*
- (2021) Gül Kilinç et al. IMMUNOLOGICAL REVIEWS
- Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis
- (2021) Susan E. Dorman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Repurposing Immunomodulatory Drugs to Combat Tuberculosis
- (2021) Samreen Fatima et al. Frontiers in Immunology
- Discovery of novel nitrogenous heterocyclic-containing quinoxaline-1,4-di-N-oxides as potent activator of autophagy in M.tb-infected macrophages
- (2021) Heying Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Genetic Profile of Linezolid-Resistant M. tuberculosis Clinical Strains from Moscow
- (2021) Anastasia Ushtanit et al. Antibiotics-Basel
- Treatment of Highly Drug-Resistant Pulmonary Tuberculosis
- (2020) Francesca Conradie et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of pyrvinium pamoate as an anti-tuberculosis agent in vitro and in vivo by SOSA approach amongst known drugs
- (2020) Qing Guan et al. Emerging Microbes & Infections
- Repurposed drug candidates for antituberculosis therapy
- (2020) Qi An et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Host-Directed Therapies and Anti-Virulence Compounds to Address Anti-Microbial Resistant Tuberculosis Infection
- (2020) Raphael Gries et al. Applied Sciences-Basel
- Development of Macozinone for TB treatment: An Update
- (2020) Vadim Makarov et al. Applied Sciences-Basel
- New Drug Approvals for 2019: Synthesis and Clinical Applications
- (2020) Shuo Yuan et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Molecular characteristics and in vitro susceptibility to bedaquiline of Mycobacterium tuberculosis isolates circulating in Shaanxi, China
- (2020) Jian Yang et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Hydroxylation of Antitubercular Drug Candidate, SQ109, by Mycobacterial Cytochrome P450
- (2020) Sergey Bukhdruker et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Development of Rifapentine-Loaded PLGA-Based Nanoparticles: In vitro Characterisation and in vivo Study in Mice
- (2020) Qiuzhen Liang et al. International Journal of Nanomedicine
- Characterization of Genomic Variants Associated with Resistance to Bedaquiline and Delamanid in Naive Mycobacterium tuberculosis Clinical Strains
- (2020) S. Battaglia et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Mannose receptor targeted bioadhesive chitosan nanoparticles of clofazimine for effective therapy of tuberculosis
- (2020) Datta Maroti Pawde et al. SAUDI PHARMACEUTICAL JOURNAL
- In vitro Study of Bedaquiline Resistance in Mycobacterium tuberculosis Multi-Drug Resistant Clinical Isolates
- (2020) Giulia Degiacomi et al. Frontiers in Microbiology
- Inhalable solid lipid nanoparticles for intracellular tuberculosis infection therapy: macrophage-targeting and pH-sensitive properties
- (2020) Cheng Ma et al. Drug Delivery and Translational Research
- Novel Treatments against Mycobacterium tuberculosis Based on Drug Repurposing
- (2020) Álvaro Mourenza et al. Antibiotics-Basel
- Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis
- (2020) Songuigama Coulibaly et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- An appraisal of anti-mycobacterial activity with structure-activity relationship of piperazine and its analogues: A review
- (2020) Pankaj S. Girase et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Engineering precision nanoparticles for drug delivery
- (2020) Michael J. Mitchell et al. NATURE REVIEWS DRUG DISCOVERY
- Novel Approaches for the Treatment of Pulmonary Tuberculosis
- (2020) Zhi Ming Tan et al. Pharmaceutics
- Polypeptidic Micelles Stabilized with Sodium Alginate Enhance the Activity of Encapsulated Bedaquiline
- (2019) Héctor Soria-Carrera et al. MACROMOLECULAR BIOSCIENCE
- The bowel preparation for magnetic resonance enterography in patients with Crohn’s disease: study protocol for a randomized controlled trial
- (2019) Min Dai et al. Trials
- Peptidyl-prolyl isomerase-B is involved in Mycobacterium tuberculosis biofilm formation and a generic target for drug repurposing-based intervention
- (2019) Ashutosh Kumar et al. npj Biofilms and Microbiomes
- Evaluation of metformin in combination with rifampicin containing antituberculosis therapy in patients with new, smear-positive pulmonary tuberculosis (METRIF): study protocol for a randomised clinical trial
- (2019) Chandrasekaran Padmapriyadarsini et al. BMJ Open
- Enhanced antitubercular activity, alveolar deposition and macrophages uptake of mannosylated stable nanoliposomes
- (2019) Amira Hamed et al. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
- Improving treatment outcomes for MDR-TB — Novel host-directed therapies and personalised medicine of the future
- (2019) Martin Rao et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Introducing RpsA Point Mutations Δ438A and D123A into the Chromosome of M. tuberculosis Confirms their Role in Causing Resistance to Pyrazinamide
- (2019) Wanliang Shi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- First time in human (FTIH) study and prediction of early bactericidal activity for GSK3036656, a potent Leucyl - tRNA synthetase inhibitor for tuberculosis treatment
- (2019) David Tenero et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- 3,5-Dialkoxypyridine analogues of bedaquiline are potent antituberculosis agents with minimal inhibition of the hERG channel
- (2019) Hamish S. Sutherland et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Opportunities for Overcoming Mycobacterium tuberculosis Drug Resistance: Emerging Mycobacterial Targets and Host-Directed Therapy
- (2019) Eveline Torfs et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Alginate modified-PLGA nanoparticles entrapping amikacin and moxifloxacin as a novel host-directed therapy for multidrug-resistant tuberculosis
- (2019) Sharif Abdelghany et al. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
- Recent updates on drug resistance in Mycobacterium tuberculosis
- (2019) R. Singh et al. JOURNAL OF APPLIED MICROBIOLOGY
- A Repurposing Approach for Uncovering the Anti-Tubercular Activity of FDA-Approved Drugs with Potential Multi-Targeting Profiles
- (2019) Basem Battah et al. MOLECULES
- Therapeutic host-directed strategies to improve outcome in tuberculosis
- (2019) C. Young et al. Mucosal Immunology
- Analysis of mutations leading to para-aminosalicylic acid resistance in Mycobacterium tuberculosis
- (2019) Bharati Pandey et al. Scientific Reports
- New Drugs for the Treatment of Tuberculosis
- (2019) Elisa H. Ignatius et al. CLINICS IN CHEST MEDICINE
- Structural Dynamics Behind Clinical Mutants of PncA-Asp12Ala, Pro54Leu, and His57Pro of Mycobacterium tuberculosis Associated With Pyrazinamide Resistance
- (2019) Aamir Mehmood et al. Frontiers in Bioengineering and Biotechnology
- Ambroxol induces autophagy and potentiates Rifampin antimycobacterial activity
- (2018) Seong Won Choi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Verapamil Targets Membrane Energetics in Mycobacterium tuberculosis
- (2018) Chao Chen et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Hit Generation in TB Drug Discovery: From Genome to Granuloma
- (2018) Tianao Yuan et al. CHEMICAL REVIEWS
- Drug discovery in tuberculosis. New drug targets and antimycobacterial agents
- (2018) André Campaniço et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Mannose-functionalized solid lipid nanoparticles are effective in targeting alveolar macrophages
- (2018) Ana Costa et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Mucoadhesive chitosan-coated solid lipid nanoparticles for better management of tuberculosis
- (2018) Alexandre C.C. Vieira et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Recent advances for identification of new scaffolds and drug targets for Mycobacterium tuberculosis
- (2018) Rohan Dhiman et al. IUBMB LIFE
- Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care
- (2018) Navisha Dookie et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Daily adjunctive therapy with vitamin D3 and phenylbutyrate supports clinical recovery from pulmonary tuberculosis: a randomized controlled trial in Ethiopia
- (2018) A. Bekele et al. JOURNAL OF INTERNAL MEDICINE
- Antimicrobial activity against Mycobacterium tuberculosis under in vitro lipid-rich dormancy conditions
- (2018) Diana Angelica Aguilar-Ayala et al. JOURNAL OF MEDICAL MICROBIOLOGY
- Development and evaluation of Chitosan nanoparticles based dry powder inhalation formulations of Prothionamide
- (2018) Sujit Kumar Debnath et al. PLoS One
- Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824)
- (2018) Rafael Baptista et al. Scientific Reports
- Molecular Targets Related Drug Resistance Mechanisms in MDR-, XDR-, and TDR-Mycobacterium tuberculosis Strains
- (2018) H. M. Adnan Hameed et al. Frontiers in Cellular and Infection Microbiology
- The Expanding Diversity of Mycobacterium tuberculosis Drug Targets
- (2018) Samantha Wellington et al. ACS Infectious Diseases
- Mutations inside rifampicin-resistance determining region of rpoB gene associated with rifampicin-resistance in Mycobacterium tuberculosis
- (2018) Myo T. Zaw et al. Journal of Infection and Public Health
- An optimized background regimen for treatment of active tuberculosis with the next-generation benzothiazinone Macozinone (PBTZ169)
- (2018) Andréanne Lupien et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Chitosan nanoparticles as a promising approach for pulmonary delivery of bedaquiline
- (2018) Tejal Rawal et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- The drug repurposing landscape from 2012 to 2017: evolution, challenges, and possible solutions
- (2018) Prasanthi Polamreddy et al. DRUG DISCOVERY TODAY
- Autophagy: A new strategy for host-directed therapy of tuberculosis
- (2018) Seungwha Paik et al. Virulence
- Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study
- (2017) Sergey E. Borisov et al. EUROPEAN RESPIRATORY JOURNAL
- Identification of novel mutations associated with cycloserine resistance in Mycobacterium tuberculosis
- (2017) Jiazhen Chen et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Discovery of a Potent and Specific M. tuberculosis Leucyl-tRNA Synthetase Inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656)
- (2017) Xianfeng Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- Origins of Combination Therapy for Tuberculosis: Lessons for Future Antimicrobial Development and Application
- (2017) Christopher A. Kerantzas et al. mBio
- Non-Steroidal Anti-inflammatory Drugs As Host-Directed Therapy for Tuberculosis: A Systematic Review
- (2017) Vera M. Kroesen et al. Frontiers in Immunology
- Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles
- (2017) Joana Costa-Gouveia et al. Scientific Reports
- Dry powder inhalable formulations for anti-tubercular therapy
- (2016) Thaigarajan Parumasivam et al. ADVANCED DRUG DELIVERY REVIEWS
- New agents for the treatment of drug-resistant Mycobacterium tuberculosis
- (2016) Daniel T. Hoagland et al. ADVANCED DRUG DELIVERY REVIEWS
- Mycobacterium tuberculosis Mutations Associated with Reduced Susceptibility to Linezolid
- (2016) Shuo Zhang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Current challenges in drug discovery for tuberculosis
- (2016) Anuradha Kumar et al. Expert Opinion on Drug Discovery
- Mefloquine and its oxazolidine derivative compound are active against drug-resistant Mycobacterium tuberculosis strains and in a murine model of tuberculosis infection
- (2016) Valnês S. Rodrigues-Junior et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Delamanid susceptibility testing ofMycobacterium tuberculosisusing the resazurin microtitre assay and the BACTEC™ MGIT™ 960 system
- (2016) Elisa Schena et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Nanotechnology-Based Drug Delivery Systems for Treatment of Tuberculosis—A Review
- (2016) Patricia Bento da Silva et al. Journal of Biomedical Nanotechnology
- A Multilaboratory, Multicountry Study To Determine Bedaquiline MIC Quality Control Ranges for Phenotypic Drug Susceptibility Testing
- (2016) Koné Kaniga et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Granulomas and Inflammation: Host-Directed Therapies for Tuberculosis
- (2016) Hlumani Ndlovu et al. Frontiers in Immunology
- High-dose vitamin D3 in adults with pulmonary tuberculosis: a double-blind randomized controlled trial
- (2015) Nestan Tukvadze et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- Bactericidal Activity of Pyrazinamide and Clofazimine Alone and in Combinations with Pretomanid and Bedaquiline
- (2015) Andreas H. Diacon et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Improving the Tuberculosis Drug Development Pipeline
- (2015) Dimitrios Evangelopoulos et al. Chemical Biology & Drug Design
- Advances in nanotechnology-based carrier systems for targeted delivery of bioactive drug molecules with special emphasis on immunotherapy in drug resistant tuberculosis – a critical review
- (2015) Jagdeep Singh et al. DRUG DELIVERY
- Bedaquiline and delamanid in tuberculosis
- (2015) Susanna Esposito et al. EXPERT OPINION ON PHARMACOTHERAPY
- Repurposing—a ray of hope in tackling extensively drug resistance in tuberculosis
- (2015) Arundhati Maitra et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients
- (2015) Norbert Heinrich et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Nanotechnology approaches for inhalation treatment of lung diseases
- (2015) Andriy Kuzmov et al. JOURNAL OF CONTROLLED RELEASE
- The association between sterilizing activity and drug distribution into tuberculosis lesions
- (2015) Brendan Prideaux et al. NATURE MEDICINE
- Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis
- (2015) Michael B. Harbut et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review
- (2015) Dilara Kiran et al. Seminars in Immunopathology
- Tuberculosis Treatment and Drug Regimens
- (2015) G. Sotgiu et al. Cold Spring Harbor Perspectives in Medicine
- Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?
- (2015) Stephen K. Field Therapeutic Advances in Chronic Disease
- Population Pharmacokinetic/Pharmacodynamic Analysis of the Bactericidal Activities of Sutezolid (PNU-100480) and Its Major Metabolite against Intracellular Mycobacterium tuberculosis inEx VivoWhole-Blood Cultures of Patients with Pulmonary Tuberculosis
- (2014) Tong Zhu et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroSusceptibility of Mycobacterium tuberculosis Isolates to an Oral Carbapenem Alone or in Combination with β-Lactamase Inhibitors
- (2014) Yasuhiro Horita et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Genetic Determinants Involved inp-Aminosalicylic Acid Resistance in Clinical Isolates from Tuberculosis Patients in Northern China from 2006 to 2012
- (2014) Xiaobing Zhang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A Novel Inhibitor of Gyrase B Is a Potent Drug Candidate for Treatment of Tuberculosis and Nontuberculosis Mycobacterial Infections
- (2014) Christopher P. Locher et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Towards a new combination therapy for tuberculosis with next generation benzothiazinones
- (2014) V. Makarov et al. EMBO Molecular Medicine
- Reduced 15-lipoxygenase 2 and lipoxin A4/leukotriene B4 ratio in children with cystic fibrosis
- (2014) F. C. Ringholz et al. EUROPEAN RESPIRATORY JOURNAL
- Inflammation and tuberculosis: host-directed therapies
- (2014) A. Zumla et al. JOURNAL OF INTERNAL MEDICINE
- Second-Generation Antibacterial Benzimidazole Ureas: Discovery of a Preclinical Candidate with Reduced Metabolic Liability
- (2014) Anne-Laure Grillot et al. JOURNAL OF MEDICINAL CHEMISTRY
- The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells
- (2014) Véronique Dartois NATURE REVIEWS MICROBIOLOGY
- Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis
- (2014) Stephen H. Gillespie et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline
- (2014) Andreas H. Diacon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mycobactericidal Activity of Sutezolid (PNU-100480) in Sputum (EBA) and Blood (WBA) of Patients with Pulmonary Tuberculosis
- (2014) Robert S. Wallis et al. PLoS One
- Identification of Host-Targeted Small Molecules That Restrict Intracellular Mycobacterium tuberculosis Growth
- (2014) Sarah A. Stanley et al. PLoS Pathogens
- Vitamin D accelerates clinical recovery from tuberculosis: results of the SUCCINCT Study [Supplementary Cholecalciferol in recovery from tuberculosis]. A randomized, placebo-controlled, clinical trial of vitamin D supplementation in patients with pulmonary tuberculosis’
- (2013) Nawal Salahuddin et al. BMC INFECTIOUS DISEASES
- Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis
- (2013) Kevin Pethe et al. NATURE MEDICINE
- Correction: Whole Cell Screen for Inhibitors of pH Homeostasis in Mycobacterium tuberculosis
- (2013) Crystal M. Darby et al. PLoS One
- Identification of a small molecule with activity against drug-resistant and persistent tuberculosis
- (2013) F. Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis
- (2013) Shuo Zhang et al. Emerging Microbes & Infections
- Streptomycin-Starved Mycobacterium tuberculosis 18b, a Drug Discovery Tool for Latent Tuberculosis
- (2012) Ming Zhang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Extracellular M. tuberculosis DNA Targets Bacteria for Autophagy by Activating the Host DNA-Sensing Pathway
- (2012) Robert O. Watson et al. CELL
- Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis
- (2012) Vija Skripconoka et al. EUROPEAN RESPIRATORY JOURNAL
- Antituberculosis therapy for 2012 and beyond
- (2012) Michael Lauzardo et al. EXPERT OPINION ON PHARMACOTHERAPY
- Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action
- (2012) Katherine A Sacksteder et al. Future Microbiology
- 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial
- (2012) Andreas H Diacon et al. LANCET
- Delamanid for Multidrug-Resistant Pulmonary Tuberculosis
- (2012) Maria Tarcela Gler et al. NEW ENGLAND JOURNAL OF MEDICINE
- Composition Influence on Pulmonary Delivery of Rifampicin Liposomes
- (2012) Maria Manca et al. Pharmaceutics
- Impact of the E540V Amino Acid Substitution in GyrB ofMycobacterium tuberculosison Quinolone Resistance
- (2011) Hyun Kim et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Synergistic Drug Combinations for Tuberculosis Therapy Identified by a Novel High-Throughput Screen
- (2011) Santiago Ramón-García et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Association of mutation patterns in gyrA/B genes and ofloxacin resistance levels in Mycobacterium tuberculosisisolates from East China in 2009
- (2011) Zhenling Cui et al. BMC INFECTIOUS DISEASES
- Niosomal encapsulation of the antitubercular drug, pyrazinamide
- (2011) Mohammed Shafik El-Ridy et al. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
- Navigating tuberculosis drug discovery with target-based screening
- (2011) Christopher H Miller et al. Expert Opinion on Drug Discovery
- Challenges and opportunities in developing novel drugs for TB
- (2011) Takushi Kaneko et al. Future Medicinal Chemistry
- The challenge of new drug discovery for tuberculosis
- (2011) Anil Koul et al. NATURE
- Molecular Investigation of Resistance to the Antituberculous Drug Ethionamide in Multidrug-Resistant Clinical Isolates ofMycobacterium tuberculosis
- (2010) F. Brossier et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effect of surface-mannose modification on aerosolized liposomal delivery to alveolar macrophages
- (2010) Sumio Chono et al. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
- Safety, Tolerability, and Pharmacokinetics of PA-824 in Healthy Subjects
- (2009) A. M. Ginsberg et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Vitamin D3 Induces Autophagy in Human Monocytes/Macrophages via Cathelicidin
- (2009) Jae-Min Yuk et al. Cell Host & Microbe
- Linezolid in the Treatment of Multidrug‐Resistant Tuberculosis
- (2009) G. F. Schecter et al. CLINICAL INFECTIOUS DISEASES
- Apoptosis and autophagy: Targeting autophagy signalling in cancer cells -‘trick or treats’?
- (2009) Elisabeth A. Corcelle et al. FEBS Journal
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started